Livzon Pharmaceutical Group Inc. (SHE:000513)

SHE:000513 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Jan 1, 2021
Cash & Equivalents	10,352	10,827	11,326	10,411	9,146	9,954
Trading Asset Securities	258.32	89.36	81.79	108.09	182.77	25.98
Cash & Short-Term Investments	10,825	10,917	11,408	10,519	9,329	9,980
Cash Growth	-6.41%	-4.30%	8.44%	12.76%	-6.52%	12.48%
Accounts Receivable	3,445	3,249	3,575	4,039	3,294	2,892
Other Receivables	61.81	59.28	51.91	31.32	64.37	92.85
Receivables	3,507	3,308	3,627	4,071	3,358	2,985
Inventory	1,715	1,998	2,061	2,045	1,663	1,488
Other Current Assets	191.82	197.44	171.11	352	322.42	174.88
Total Current Assets	16,238	16,420	17,266	16,987	14,673	14,627
Property, Plant & Equipment	4,437	4,537	4,566	4,592	4,239	3,707
Long-Term Investments	1,893	1,618	1,670	1,738	1,695	988.09
Goodwill	124.91	124.91	124.91	103.04	103.04	103.04
Other Intangible Assets	491.67	403.68	426.28	557.44	260.28	236.43
Long-Term Deferred Tax Assets	383.94	356.35	301.92	283.89	252.69	238.23
Long-Term Deferred Charges	454.9	396.25	468.62	416.74	704.41	373.49
Other Long-Term Assets	148.71	599.54	221.17	189.66	444.62	317.09
Total Assets	24,173	24,456	25,045	24,868	22,372	20,591
Accounts Payable	1,390	1,584	1,658	1,862	1,817	1,625
Accrued Expenses	3,088	3,109	3,295	3,249	2,656	2,467
Short-Term Debt	2,130	2,455	1,860	1,622	2,043	1,551
Current Portion of Long-Term Debt	93.97	36.21	647.47	-	-	-
Current Portion of Leases	12.84	12.53	12.2	10.44	9.28	8.54
Current Income Taxes Payable	125.73	112.88	181.58	92.57	97.45	179.51
Current Unearned Revenue	71.79	124.63	138	226.19	167.8	104.45
Other Current Liabilities	497.09	191.27	294.49	334.42	134.34	147.17
Total Current Liabilities	7,410	7,625	8,087	7,397	6,925	6,083
Long-Term Debt	1,368	1,466	1,613	1,974	636.78	360.32
Long-Term Leases	15.12	13.1	9.03	11.61	5.27	10.1
Long-Term Unearned Revenue	245.66	238.42	269.37	273.21	258.88	276.14
Long-Term Deferred Tax Liabilities	210.55	207.39	209.81	191.96	156.89	143.28
Other Long-Term Liabilities	-	-	90	84	78	78
Total Liabilities	9,249	9,550	10,278	9,932	8,061	6,951
Common Stock	904.1	911.35	923.94	935.55	937.87	944.84
Additional Paid-In Capital	320.95	529.24	1,322	1,422	1,629	1,457
Retained Earnings	12,798	12,506	11,653	11,182	10,461	9,682
Treasury Stock	-406.9	-196.62	-	-55.94	-71.21	-250.06
Comprehensive Income & Other	61.5	112.18	143.07	391.64	46.55	273.78
Total Common Equity	13,678	13,862	14,042	13,876	13,004	12,107
Minority Interest	1,246	1,043	724.21	1,060	1,307	1,533
Shareholders' Equity	14,924	14,906	14,767	14,936	14,311	13,640
Total Liabilities & Equity	24,173	24,456	25,045	24,868	22,372	20,591
Total Debt	3,620	3,983	4,141	3,619	2,694	1,930
Net Cash (Debt)	7,205	6,934	7,266	6,901	6,635	8,050
Net Cash Growth	-4.28%	-4.57%	5.29%	4.01%	-17.58%	7.16%
Net Cash Per Share	7.94	7.53	7.81	7.37	7.09	8.58
Filing Date Shares Outstanding	892.78	908.91	923.94	932.23	929.97	932.47
Total Common Shares Outstanding	892.78	908.91	923.94	932.23	929.97	944.84
Working Capital	8,828	8,795	9,179	9,591	7,748	8,544
Book Value Per Share	15.32	15.25	15.20	14.88	13.98	12.81
Tangible Book Value	13,061	13,334	13,491	13,216	12,640	11,768
Tangible Book Value Per Share	14.63	14.67	14.60	14.18	13.59	12.45
Buildings	3,931	3,912	3,745	-	3,123	2,970
Machinery	4,900	4,817	4,551	7,577	3,764	3,216
Construction In Progress	287.18	257.37	289.31	602.44	554.58	385.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.